Program
Sirolimus
Also written as “sirolimus”, “Rapamycin” and “Sirolimus for Injection (Albumin-bound)”.
Its studies are mostly in Renal Insufficiency · Kidney Failure, Chronic · Breast Neoplasms · Tuberous Sclerosis · Uveitis, led by 18 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 260 open or running | phase 4since Sep 4, 2002 | May 17, 2002 | none ahead |
| CSPC Pharmaceutical Group | 85 open or running | phase 3since Apr 8, 2025 | Oct 25, 2021 | Oct 2027phase 1 · NCT06941142 |
| Santen Pharmaceutical | 70 open or running | phase 3since May 19, 2011 | Nov 15, 2006 | none ahead |
| Astellas Pharma | 31 open or running | phase 4since May 31, 2011 | May 31, 2011 | Oct 31, 2027phase 2 · NCT07052929 |
| Umoja Biopharma | 33 open or running | phase 2since Jul 24, 2026 | Jul 25, 2024 | Mar 2029phase 1 · NCT06528301 |
| AgelessRx | 21 open or running | phase 3since Dec 18, 2024 | Jul 13, 2020 | none ahead |
| Dr. Reddy's Laboratories | 20 open or running | phase 1since Nov 18, 2014 | Nov 18, 2014 | none ahead |
| Hoffmann-La Roche | 20 open or running | phase 4since Jul 15, 2005 | Jul 15, 2005 | none ahead |
| Nobelpharma | 20 open or running | phase 1since Dec 3, 2018 | Dec 3, 2018 | none ahead |
| Vascular Therapies | 20 open or running | phase 3since Jul 29, 2015 | Jul 29, 2015 | none ahead |
| aft-pharmaceuticals-ltd | 11 open or running | phase 2since Feb 22, 2026 | Feb 22, 2026 | Oct 2027phase 2 · NCT07436611 |
| aucta-pharmaceuticals-inc | 10 open or running | phase 2since Dec 1, 2017 | Dec 1, 2017 | none ahead |
| Chong Kun Dang Pharmaceutical | 11 open or running | phase 4since Jan 3, 2022 | Jan 3, 2022 | none ahead |
| concept-medical-inc | 11 open or running | phase 3since Jan 21, 2026 | Jan 21, 2026 | Dec 2027phase 3 · NCT07359807 |
| dermatology-specialties-limited-partnership | 10 open or running | phase 3since Jan 29, 2019 | Jan 29, 2019 | none ahead |
| Eli Lilly | 11 open or running | phase 2since May 11, 2020 | May 11, 2020 | Feb 2027phase 2 · NCT04411654 |
| nanjing-iaso-biotechnology-co-ltd | 11 open or running | phase 1since Dec 10, 2024 | Dec 10, 2024 | May 21, 2028phase 1 · NCT06743503 |
| transderm-inc | 10 open or running | phase 1since Feb 5, 2014 | Feb 5, 2014 | none ahead |
- Named in CSPC Pharmaceutical Group’s own pipeline as
sirolimus for injection (albumin-bound)
, phase 4, as of Aug 20, 2026 (source).
Also a collaborator on its studies: basilea-pharmaceutica-international-ltd and macusight-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Aug 1, 2005.
- Nov 14, 2022Phase 2 study in Perivascular Epithelioid Cell NeoplasmsCSPC Pharmaceutical Group · NCT05625919 · 54 enrolled · China
- Jul 25, 2024Umoja Biopharma's first study: phase 1 study in Lymphoma, B-CellNew to Umoja BiopharmaUmoja Biopharma · NCT06528301 · 106 planned · United States, Australia
- Dec 10, 2024nanjing-iaso-biotechnology-co-ltd's first study: phase 1 study in RecurrenceNew to nanjing-iaso-biotechnology-co-ltdnanjing-iaso-biotechnology-co-ltd · NCT06743503 · 70 planned · China
- Dec 18, 2024Phase 3 study in LongevityAgelessRx · NCT07092618 · 150 planned · United States
- Apr 8, 2025Phase 3 study in Breast NeoplasmsCSPC Pharmaceutical Group · NCT06929325 · 312 planned · China
- Apr 16, 2025Phase 1 study in Advanced Breast CancerCSPC Pharmaceutical Group · NCT06941142 · 382 planned
- Apr 26, 2025Phase 2 study in Breast NeoplasmsCSPC Pharmaceutical Group · NCT06957379 · 78 enrolled · China
- Jun 30, 2025Phase 2 study in Myopathies, Structural, CongenitalAstellas Pharma · NCT07052929 · 9 planned · United States, Canada
- Sep 3, 2025Phase 3 study in Gastroenteropancreatic Neuroendocrine TumorsCSPC Pharmaceutical Group · NCT07165886 · 298 planned · China
- Jan 21, 2026concept-medical-inc's first study: phase 3 study in Peripheral Arterial DiseaseNew to concept-medical-incconcept-medical-inc · NCT07359807 · 478 planned
- Feb 22, 2026aft-pharmaceuticals-ltd's first study: phase 2 study in Hemangioma, CapillaryNew to aft-pharmaceuticals-ltdaft-pharmaceuticals-ltd · NCT07436611 · 30 planned · United States, Spain
- Jun 29, 2026Phase 2 study in Hemangioendothelioma, EpithelioidCSPC Pharmaceutical Group · NCT07684287 · 40 planned · China
- Jul 24, 2026Phase 1 study in Multiple MyelomaUmoja Biopharma · NCT07735546 · 100 planned · Australia
- Jul 24, 2026Phase 2 study in Lymphoma, B-CellPhase 2 reachedUmoja Biopharma · NCT07735533 · 274 planned · United States
Ahead
- Feb 2027Primary completion: phase 2 study in Gaucher DiseaseEli Lilly · NCT04411654
- Oct 2027Primary completion: phase 2 study in Hemangioma, Capillaryaft-pharmaceuticals-ltd · NCT07436611
- Oct 2027Primary completion: phase 1 study in Advanced Breast CancerCSPC Pharmaceutical Group · NCT06941142
- Oct 31, 2027Primary completion: phase 2 study in Myopathies, Structural, CongenitalAstellas Pharma · NCT07052929
TargetBeta
“A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian …”NCIt, read by Claude
“FK506-binding protein 1A inhibitor”ChEMBL 37, by rule
Other programs on MTOR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| gedatolisibrule | Pfizer | phase 3 | 9 |
| PI3K/mTOR Kinase Inhibitor WXFL10030390rule | shanghai-jiatan-pharmatech-co-ltd | phase 3 | 6 |
| sapanisertibrule | Takeda | phase 2 | 14 |
Studies
The newest 60 of 65 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07735546Multiple Myeloma · Australia | 1 | Recruiting | Umoja Biopharma | Dec 31, 2029 | 100 |
| NCT07735533Lymphoma, B-Cell · United States | 2 | Recruiting | Umoja Biopharma | Aug 2031 | 274 |
| NCT07684287Hemangioendothelioma, Epithelioid · China | 2 | Not yet recruiting | CSPC Pharmaceutical Group | Nov 30, 2027 | 40 |
| NCT07436611Hemangioma, Capillary · United States, Spain | 2 | Not yet recruiting | aft-pharmaceuticals-ltd | Oct 2027 | 30 |
| NCT07359807Peripheral Arterial Disease | 3 | Not yet recruiting | concept-medical-inc | Dec 2027 | 478 |
| NCT07165886Gastroenteropancreatic Neuroendocrine Tumors · China | 3 | Recruiting | CSPC Pharmaceutical Group | Aug 29, 2028 | 298 |
| NCT07052929Myopathies, Structural, Congenital · United States, Canada | 2 | Recruiting | Astellas Pharma | Oct 31, 2027 | 9 |
| NCT06957379Breast Neoplasms · China | 2 | Active, not recruiting | CSPC Pharmaceutical Group | Jun 2025 | 78 |
| NCT06941142Advanced Breast Cancer | 1 | Not yet recruiting | CSPC Pharmaceutical Group | Oct 2027 | 382 |
| NCT06929325Breast Neoplasms · China | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Oct 2026 | 312 |
| NCT07092618Longevity · United States | 3 | Recruiting | AgelessRx | Aug 2025 | 150 |
| NCT06743503Recurrence · China | 1 | Recruiting | nanjing-iaso-biotechnology-co-ltd | May 21, 2028 | 70 |
| NCT06528301Lymphoma, B-Cell · United States, Australia | 1 | Recruiting | Umoja Biopharma | Mar 2029 | 106 |
| NCT05625919Perivascular Epithelioid Cell Neoplasms · China | 2 | UNKNOWN | CSPC Pharmaceutical Group | Nov 2024 | 54 |
| NCT05508620Malignant Solid Tumors | 1 | UNKNOWN | CSPC Pharmaceutical Group | Dec 2024 | 270 |
| NCT05425056Kidney Failure, Chronic · United States, United Kingdom | 3 | Completed | Vascular Therapies | Mar 18, 2025 | 136 |
| NCT05193565Kidney Transplantation · South Korea | 4 | Active, not recruiting | Chong Kun Dang Pharmaceutical | Jul 2026 | 206 |
| NCT05125523Advanced Solid Tumors · China | 1 | UNKNOWN | CSPC Pharmaceutical Group | Jun 2024 | 264 |
| NCT04488601Aging · United States | 2 | Completed | AgelessRx | Dec 30, 2023 | 129 |
| NCT04411654Gaucher Disease · United States, United Kingdom | 2 | Active, not recruiting | Eli Lilly | Feb 2027 | 7 |
| NCT03972462Bioavailability Study · United States | 1 | Completed | Nobelpharma | Jun 17, 2019 | 12 |
| NCT03826628Tuberous Sclerosis · United States, Australia, Czechia and more | 3 | Completed | dermatology-specialties-limited-partnership | Sep 1, 2022 | 107 |
| NCT03765944Bioequivalence Study · Japan | 1 | Completed | Nobelpharma | Dec 29, 2018 | 10 |
| NCT03363763Tuberous Sclerosis · United States, China | 2 | Terminated | aucta-pharmaceuticals-inc | Mar 24, 2023 | 24 |
| NCT02686619Renal Transplantation · France | 3 | Completed | Hoffmann-La Roche | Jan 2011 | 237 |
| NCT02513303Kidney Failure, Chronic · United States | 3 | Completed | Vascular Therapies | Jun 2021 | 269 |
| NCT02296762Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Feb 2010 | 36 |
| NCT02296749Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Jan 2010 | 60 |
| NCT02251938Non-Infectious Uveitis of the Posterior Segment of the Eye · United States, Austria, France and more | 3 | Completed | Santen Pharmaceutical | Nov 1, 2017 | 60 |
| NCT02152007Pachyonychia Congenita · United States | 1 | Completed | transderm-inc | Jul 2015 | 15 |
| NCT01809860Healthy Subjects · United States | 1 | Completed | Astellas Pharma | Jan 2012 | 22 |
| NCT01363752Acute Kidney Injury · Australia, Austria, Belarus and more | 4 | Completed | Astellas Pharma | Sep 18, 2013 | 853 |
| NCT01358266Uveitis · United States, Argentina, Austria and more | 3 | Completed | Santen Pharmaceutical | Sep 2016 | 592 |
| NCT01236378Transplant Rejection · China | 1 | Completed | Pfizer | Apr 2011 | 24 |
| NCT00895583Graft Rejection · United States, Argentina, Australia and more | 4 | Completed | Pfizer | Aug 2013 | 254 |
| NCT00814944Dry Eye Syndromes · United States | 2 | Completed | Santen Pharmaceutical | Oct 2009 | 143 |
| NCT00766337Macular Degeneration · United States | 2 | Terminated | Santen Pharmaceutical | Nov 2009 | 62 |
| NCT00712491Macular Degeneration · United States | 2 | Terminated | Santen Pharmaceutical | Nov 2009 | 20 |
| NCT00656643Diabetic Macular Edema · United States | 2 | Completed | Santen Pharmaceutical | Nov 2009 | 131 |
| NCT00519116Kidney Transplantation | 4 | Completed | Pfizer | 150 | |
| NCT00518375Kidney Transplantation | 4 | Completed | Pfizer | 250 | |
| NCT00518271Kidney Transplantation | 2 | Completed | Pfizer | 120 | |
| NCT00507793Kidney Transplantation | 4 | Completed | Pfizer | 385 | |
| NCT00478608Renal Transplant · Korea, Republic of | 3 | Completed | Pfizer | Nov 2008 | 79 |
| NCT00470665Renal Allograft Recipients | 3 | Completed | Pfizer | 460 | |
| NCT00452361Kidney Transplantation · Taiwan | 4 | Terminated | Pfizer | Aug 2008 | 31 |
| NCT00428064Renal Transplantation | 3 | Completed | Pfizer | 408 | |
| NCT00401115Diabetic Retinopathy · United States | 1 | Completed | Santen Pharmaceutical | Jun 2008 | 50 |
| NCT00369382Renal Insufficiency · United States, Australia, Austria and more | 4 | Completed | Pfizer | Apr 2010 | 121 |
| NCT00311311Atherosclerosis · United States, Canada | 3 | Terminated | Pfizer | Dec 2010 | 72 |
| NCT00282217Renal Insufficiency · Spain | 4 | Completed | Pfizer | 100 | |
| NCT00266123Renal Insufficiency | 4 | Completed | Pfizer | 420 | |
| NCT00261820Renal Insufficiency | 4 | Completed | Pfizer | 160 | |
| NCT00254709Renal Insufficiency | 4 | Completed | Pfizer | 66 | |
| NCT00248313Kidney Diseases | 3 | Completed | Pfizer | 470 | |
| NCT00195481Renal Insufficiency · India | 4 | Completed | Pfizer | Dec 2005 | 100 |
| NCT00195273Graft vs Host Disease · Norway, Sweden | 3 | Completed | Pfizer | Jul 2008 | 61 |
| NCT00167947Renal Insufficiency · Italy | 3 | Completed | Pfizer | Jul 2007 | 150 |
| NCT00137345Kidney Transplant · United States, Argentina, Australia and more | 3 | Terminated | Pfizer | Aug 2006 | 500 |
| NCT00129961Skin Neoplasms · United States, Australia, Canada and more | 4 | Completed | Pfizer | Jan 2009 | 86 |
How it is read
Names in the registry
- “Sirolimus”, 28 entries
- “sirolimus”, 8 entries
- “Rapamycin”, 3 entries
- “Sirolimus for Injection (Albumin-bound)”, 3 entries
- “Rapamune® (Sirolimus)”, 3 entries
Conditions, from the studies’ own filings
- Renal Insufficiency, 7 studies
- Kidney Failure, Chronic, 3 studies
- Breast Neoplasms, 3 studies
- Tuberous Sclerosis, 2 studies
- Uveitis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.